Research programme: anti-infectives - MerLion/Oscient
Alternative Names: Anti-infectives research programme - MerLion/OscientLatest Information Update: 17 May 2005
Price :
$50 *
At a glance
- Originator MerLion Pharmaceuticals; Oscient Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 17 May 2005 Discontinued - Preclinical for Bacterial infections in USA (unspecified route)
- 13 Apr 2004 Genome Therapeutics is now called Oscient Pharmaceuticals
- 12 Feb 2004 Genome Therapeutics has merged with GeneSoft Pharmaceuticals